Experimental Hematology
Volume 35, Issue 3 , Pages 434-442 , March 2007

Metalloprotease inhibitors block release of soluble CD27 and enhance the immune stimulatory activity of chronic lymphocytic leukemia cells

  • Kazunori Kato

      Affiliations

    • Division of Hematology/Oncology, Department of Medicine and the UCSD Human Gene Therapy Program, UCSD School of Medicine, La Jolla, Calif., USA
    • Department of Molecular Medicine, Sapporo Medical University, Sapporo, Japan
    • Corresponding Author InformationOffprint requests to: Kazunori Kato, Ph.D., Department of Molecular Medicine, Sapporo Medical University, South 1, West 17, Sapporo 060-8556, Japan
    • ,
  • Peter Chu

      Affiliations

    • Division of Hematology/Oncology, Department of Medicine and the UCSD Human Gene Therapy Program, UCSD School of Medicine, La Jolla, Calif., USA
    • ,
  • Satoshi Takahashi

      Affiliations

    • Division of Molecular Therapy, The Institute of Medical Science, The University of Tokyo, Minato-ku, Tokyo, Japan
    • ,
  • Hirofumi Hamada

      Affiliations

    • Department of Molecular Medicine, Sapporo Medical University, Sapporo, Japan
    • ,
  • Thomas J. Kipps

      Affiliations

    • Division of Hematology/Oncology, Department of Medicine and the UCSD Human Gene Therapy Program, UCSD School of Medicine, La Jolla, Calif., USA
    • Moores UCSD Cancer Center, La Jolla, Calif., USA

Received 8 May 2006 ,Revised 5 October 2006 ,Accepted 30 October 2006.

References 

  1. Camerini D, Walz G, Loenen WA, Borst J, Seed B. The T cell activation antigen CD27 is a member of the nerve growth factor/tumor necrosis factor receptor gene family. J Immunol. 1991;147:3165–3169
  2. Maurer D, Holter W, Majdic O, Fischer GF, Knapp W. CD27 expression by a distinct subpopulation of human B lymphocytes. Eur J Immunol. 1990;20:2679–2684
  3. Ranheim EA, Cantwell MJ, Kipps TJ. Expression of CD27 and its ligand, CD70, on chronic lymphocytic leukemia B cells. Blood. 1995;85:3556–3565
  4. Hintzen RQ, De Jong R, Hack CE, et al. A soluble form of the human T cell differentiation antigen CD27 is released after triggering of the TcR/CD3 complex. J Immunol. 1991;147:29–35
  5. van Oers MHJ, Pals ST, Evers LM, et al. Expression and release of CD27 in human B-cell malignancies. Blood. 1993;82:3430–3436
  6. Molica S, Vitelli G, Levato D, et al. CD27 in B-cell chronic lymphocytic leukemia. Cellular expression, serum release and correlation with other soluble molecules belonging to nerve growth factor receptors (NGFr) superfamily. Haematologica. 1998;83:398–402
  7. Kok M, Bonfrer JM, Korse CM, de Jong D, Kersten MJ. Serum soluble CD27, but not thymidine kinase, is an independent prognostic factor for outcome in indolent Non-Hodgkin's lymphoma. Tumor Biology. 2003;24:53–60
  8. Nilsson A, de Milito A, Mowafi F, et al. Expression of CD27-CD70 on early B cell progenitors in the bone marrow: implication for diagnosis and therapy of childhood ALL. Exp Hematol. 2005;33:1500–1507
  9. Gearing AJH, Beckett P, Christodoulou M, et al. Processing of tumor necrosis factor-α precursor by metalloproteinases. Nature. 1994;370:555–557
  10. McGeehan GM, Becherer JD, Bast RC, et al. Regulation of tumor necrosis factor-α processing by a metalloproteinase inhibitor. Nature. 1994;370:558–561
  11. Kayagaki N, Kawasaki A, Ebata T, et al. Metalloproteinase-mediated release of human Fas ligand. J Exp Med. 1995;182:1777–1783
  12. Kato K, Santana-Sahagún E, Rassenti LZ, et al. The soluble CD40-ligand sCD154 in systemic lupus erythematosus. J Clin Invest. 1999;104:947–955
  13. Kipps TJ. Chronic lymphocytic leukemia and related diseases. In:  Beutler E,  Lichtman MA,  Coller BS,  Kipps TJ editor. Williams Hematology. 5th ed.. New York: McGraw-Hill; 1995;p. 1017–1039
  14. Caligaris-Cappio F. B-chronic lymphocytic leukemia: a malignancy of anti-self B cells. Blood. 1996;87:2615–2620
  15. Ranheim EA, Kipps TJ. Activated T cells induce expression of B7/BB1 on normal or leukemic B cells through a CD40-dependent signal. J Exp Med. 1993;177:925–935
  16. Ranheim EA, Kipps TJ. Tumor necrosis factor-alpha facilitates induction of CD80 (B7-1) and CD54 on human B cells by activated T cells: complex regulation by IL-4, IL-10, and CD40L. Cell Immunol. 1995;161:226–235
  17. Dehari H, Ito Y, Nakamura T, et al. Enhanced antitumor effect of RGD fiber-modified adenovirus for gene therapy of oral cancer. Cancer Gene Ther. 2003;10:75–85
  18. Kanegae Y, Lee G, Sato Y, et al. Efficient gene activation in mammalian cells by using recombinant adenovirus expressing site-specific Cre recombinase. Nucleic Acids Res. 1995;23:3816–3821
  19. Nyberg-Hoffman C, Shabram P, Li W, Giroux D, Aguilar-Cordova E. Sensitivity and reproducibility in adenoviral infectious titer determination. Nat Med. 1997;3:808–811
  20. Kato K, Cantwell MJ, Sharma S, Kipps TJ. Gene transfer of CD40-ligand induces autologous immune recognition of chronic lymphocytic leukemia B cells. J Clin Invest. 1998;101:1133–1141
  21. Tangye SG, Liu YJ, Aversa G, Phillips JH, de Vries JE. Identification of functional human splenic memory B cells by expression of CD148 and CD27. J Exp Med. 1998;188:1691–1703
  22. Werner-Favre C, Bovia F, Schneider P, et al. IgG subclass switch capacity is low in switched and in IgM-only, but high in IgD+IgM+, post-germinal center (CD27+) human B cells. Eur J Immunol. 2001;31:243–249
  23. Klein U, Rajewsky K, Küppers R. Human immunoglobulin (Ig)M+IgD+ peripheral blood B cells expressing the CD27 cell surface antigen carry somatically mutated variable region genes: CD27 as a general marker for somatically mutated (memory) B cells. J Exp Med. 1998;188:1679–1689
  24. Dono M, Zupo S, Leanza N, et al. Heterogeneity of tonsillar subepithelial B lymphocytes, the splenic marginal zone equivalents. J Immunol. 2000;164:5596–5604
  25. Loenen WAM, De Vries E, Gravestein LA, et al. The CD27 membrane receptor, a lymphocyte-specific member of the nerve growth factor receptor family, gives rise to a soluble form by protein processing that does not involve receptor endocytosis. Eur J Immunol. 1992;22:447–455
  26. Hooper NM, Karran EH, Turner AJ. Membrane protein secretases. Biochem J. 1997;321:265–279
  27. Tak PP, Hintzen RQ, Teunissen JJ, et al. Expression of the activation antigen CD27 in rheumatoid arthritis. Clin Immunol Immunopathol. 1996;80:129–138
  28. Hintzen RQ, van Lier RA, Kuijpers KC, et al. Elevated levels of a soluble form of the T cell activation antigen CD27 in cerebrospinal fluid of multiple sclerosis patients. J Neuroimmunol. 1991;35:211–217
  29. Swaak AJ, Hintzen RQ, Huysen V, van den Brink HG, Smeenk JT. Serum levels of soluble forms of T cell activation antigens CD27 and CD25 in systemic lupus erythematosus in relation with lymphocytes count and disease course. Clin Rheumatol. 1995;14:293–300
  30. Font J, Pallares L, Martorell J, et al. Elevated soluble CD27 levels in serum of patients with systemic lupus erythematosus. Clin Immunol Immunopathol. 1996;81:239–243
  31. Odendahl M, Jacobi A, Hansen A, et al. Disturbed peripheral B lymphocyte homeostasis in systemic lupus erythematosus. J Immunol. 2000;165:5970–5979
  32. Dekkers PE, ten Hove T, Lauw FN, et al. The metalloproteinase inhibitor GI5402 inhibits endotoxin-induced soluble CD27 and CD16 release in healthy humans. Infect Immun. 2000;68:3036–3039
  33. Johnson LL, Dyer R, Hupe DJ. Matrix metalloproteinases. Curr Opin Chem Biol. 1998;2:466–471
  34. Watts TH, DeBenedette MA. T cell co-stimulatory molecules other than CD28. Curr Opin Immunol. 1999;11:286–293
  35. Lens SM, Tesselaar K, van Oers MH, van Lier RA. Control of lymphocyte function through CD27-CD70 interactions. Semin Immunol. 1998;10:491–499
  36. Jacquot S, Kobata T, Iwata S, Schlossman SF, Morimoto C. CD27/CD70 interaction contributes to the activation and the function of human autoreactive CD27+ regulatory T cells. Cell Immunol. 1997;179:48–54
  37. Jacquot S, Kobata T, Iwata S, Morimoto C, Schlossman SF. CD154/CD40 and CD70/CD27 interactions have different and sequential functions in T cell-dependent B cell responses: enhancement of plasma cell differentiation by CD27 signaling. J Immunol. 1997;159:2652–2657
  38. Takeda K, Oshima H, Hayakawa Y, et al. CD27-mediated activation of murine NK cells. J Immunol. 2000;164:1741–1745
  39. Akiba H, Nakano H, Nishinaka S, et al. CD27, a member of the tumor necrosis factor receptor superfamily, activates NF-kappaB and stress-activated protein kinase/c-Jun N-terminal kinase via TRAF2, TRAF5, and NF-kappaB-inducing kinase. J Biol Chem. 1998;273:13353–13358
  40. Yamamoto H, Kishimoto T, Minamoto S. NF-kappaB activation in CD27 signaling: involvement of TNF receptor-associated factors in its signaling and identification of functional region of CD27. J Immunol. 1998;161:4753–4759
  41. Gravestein LA, Amsen D, Boes M, et al. The TNF receptor family member CD27 signals to Jun N-terminal kinase via Traf-2. Eur J Immunol. 1998;28:2208–2216
  42. Nakano H, Sakon S, Koseki H, et al. Targeted disruption of Traf5 gene causes defects in CD40- and CD27-mediated lymphocyte activation. Proc Natl Acad Sci U S A. 1999;96:9803–9808
  43. Zapata JM, Krajewska M, Krajewski S, et al. TNFR-associated factor family protein expression in normal tissues and lymphoid malignancies. J Immunol. 2000;165:5084–5096
  44. Wierda WG, Cantwell MJ, Woods SJ, et al. CD40-ligand (CD154) gene therapy for chronic lymphocytic leukemia. Blood. 2000;96:2917–2924
  45. Agematsu K, Kobata T, Sugita K, et al. Role of CD27 in T cell immune response: analysis by recombinant soluble CD27. J Immunol. 1994;153:1421–1429
  46. Kobata T, Agematsu K, Kameoka J, Schlossman SF, Morimoto C. CD27 is a signal-transducing molecule involved in CD45RA+ naive T cell costimulation. J Immunol. 1994;153:5422–5432

PII: S0301-472X(06)00701-6

doi: 10.1016/j.exphem.2006.10.018

Experimental Hematology
Volume 35, Issue 3 , Pages 434-442 , March 2007

Article Tools

* Image Usage & Resolution